TRANSCRIPT

Q3 2025 — Sellside analyst results transcript

Q3 2025PDF · 22 pages242 KB
Investor Relations
1
Barclays Q3 2025 Results
Analyst meeting transcript - 28 October 2025
(amended in places to improve accuracy and readability)
Anna Cross, Group Finance Director
Hello everybody. Thank you so much for joining us in the middle of what I know is a really busy day
for all of you and for the market, so really appreciate you coming along. As always, let me start
with some re�ections on the key themes from our discussions on the road over the last few days.
And also, given the announcement this morning, I'll outline how we think about the acquisition of
Best Egg, both for the US Consumer Bank and more widely for the Group. But let me start �rst
with the re�ections on the Q3 results. So, whilst the absolute RoTE has clearly improved, we have
had some questions on whether or not our capital discipline in relation to the IB has afected our
relative performance. The simple answer is no, and actually we've seen good performance in
some of the areas of the Investment Bank that are inherently more capital intensive.
Speci�cally in DCM, we grew our year-to-date share in Leverage Finance by about 20 basis points
year-on-year, and we've participated in 13 of the top 20 global deals in the quarter. And then in
FICC, we performed broadly in line with our peers despite not having commodities and with a
smaller footprint in Securitised Products. And I think both of those two things were called out
across the market in Q3. We did, however, call out areas where we do need to do better and they
do overlap with our existing focus businesses that we talked to you about a few times now. That
includes, Corporate M&A and ECM, both of those are capital light. And in Equity Derivatives, our
limited presence in Asia and not having a captive retail and wealth ofering, where activity has
been strong across the market, was a relative headwind for us.
I think the other thing I would say is, capital discipline remains really important for us, and we do
believe that there are further opportunities for capital e�ciency within the IB complex. Broadly,
there is nothing that happened in Q3 that undermines that strategy addressing some other
speci�c items in the quarter. We hope our Private Credit disclosure has been useful. However, as
we've got on the road, ABS Financing has also been a focus area given Tricolor. Our ABS franchise
is market leading. It's mature and it's scaled and it's predominantly in the US, and a lot of what we
said about risk management and how we manage risk in Private Credit is directly attributable to
the ABS business. The risks from the business arises from the collateral that we fund but has not
yet been distributed and we manage that in a number of ways.

-- 1 of 22 --

Investor Relations
2
First, we are protected from �rst losses via senior funding. Second, we have long running, very
granular and high frequency credit performance data, and what that allows us to do is proactively
and appropriately size the credit protection and adjust the collateral if we feel it is necessary.
Thirdly, more than 80% of the consumer related exposures that are structured, are structured to
double A or better and less than 3% is below single A.
So now moving on to the transaction that we announced this morning, as you know, we have a
clear capital hierarchy and a high bar for investment. Best Egg meets that high bar by adding scale
and capability at the right price, generating a return on investment that is comparable to the three
highest returning UK businesses over time and being accretive to both the US Consumer Bank
and Group RoTE from 2027. As a Group matter, our distribution commitments are unafected. In
fact, we expect a circa 6 basis point net release of capital across the sale of American Airlines and
the acquisition of Best Egg.
So, what is it? Simplistically, it's a direct-to-consumer provider of US personal loans. This is a
market that we already participate in, but we lacked the capability to do it at scale. It is an originate
to distribute model and the loans are distributed through forward �ow arrangements, sourcing
consumer credit for alternative asset managers, and also through securitisations, transferring
risk and retaining a modest vertical slice of the structure. We expect the acquisition to be
accretive to USCB RoTE from 2027 and to support its mid-teens RoTE target in the medium term.
And it does so in three ways.
First, it replaces the majority of the scale lost through the loss of the American Airlines business,
and with the General Motors book acquisition, we will broadly replace all of the American Airlines
income, and the income that we gain comes from higher quality origination and servicing fees
through non-NII. And it therefore generates a higher RoTE.
Second, it improves USCB's capital e�ciency. Best Egg loans are distributed to its funding
partners and do not attract material credit risk RWAs, allowing us to grow in a capital e�cient way.
Whilst we expect to retain some personal loans, these attract a lower risk weight than for US cards,
and this will continue to be the case post-AIRB.
Third, Best Egg ofers synergies with the existing business. It expands our capabilities to originate
personal loans directly to consumers beyond our existing ofering. And these capabilities will help
enhance our proposition for co-brand partners and customers. Moreover, we are able to leverage
the capabilities and relationships in the Investment Bank, given the overlap between Best Egg's
funding partners and our Investment Bank clients and SRT investors. As a �nal comment, I want
to stress that Best Egg customers are prime, with an average FICO score of around 710 and

-- 2 of 22 --

Investor Relations
3
delinquency rates consistently below the peer average. And whilst we may retain some additional
loans in the future, I would expect that the average FICO scores for those to be higher and to
exceed 725. So with that, I'm happy to take your questions.
Perlie Mong, Bank of America
Starting with the Best Egg transaction, can you help us a bit on the cost and the impairment side
of things? It's a day one integration cost and going forward, how would impairment �ow through
it? Presumably it's origination, so you don't have a lot of direct holding of the loan. So, does that
mean impairment is also going to be quite low [versus revenues]?
Number two, I know the 2028 target is something that you would not want to talk too much about
right now. With the Best Egg transaction, we have greater visibility as to how we can get to mid-
teens for the business, and then the UK businesses, all three of them are easily making greater
than 20%. And if the Investment Bank is greater than 12% Group guidance for 2026, mechanically
I think we can get quite close to 14%. Is that aligned to the ambition that you have for the business
going forward?
Anna Cross
Okay, thank you Perlie. Let me take those in order. So the structure of Best Egg will be about $11
billion of what we call managed balances. Only about $1 billion we expect to be on the balance
sheet. So therefore, the RWA position is relatively low and the direct impact of impairment is
relatively low. So that's really what creates the stability of these returns and the relatively high
RoTE of the business. So, I'm not going to give you speci�c numbers now on impairment, but
expect it to be a relatively small number just because of the nature of the business model.
As relates to costs, clearly, again we'll update you nearer to the time around our expectations on
costs. A bit like what we did on Tesco. So, think no later than Q1, we'll give you a much fuller
breakdown of what this is likely to look like. But we do expect some opportunities in the future to
be able to generate cost synergies. In the immediate sort of short-term period we would expect
to run this business somewhat standalone and then integrate it over time, a little bit like what
we've done with the other smaller acquisitions. But I think what's really important here, and you
can see it I guess from the numbers that we've given you, is that the RoTE of this business is
extremely high. And even if you did it on an ROI basis, it remains high, and we expect to be able to
grow that over time.

-- 3 of 22 --

Investor Relations
4
On your second question, clearly I'm not going to give you a target now, but just remind you that
when we set out the targets, RoTE, distributions, and the way we expect to grow our RWAs, 2026
was the only ever supposed to be a point in time and, and a sort of near term target. What you
should be gleaning from us is that we are gaining momentum in the business, that we're gaining
con�dence in the business, and that's really what's led us to not only upgrade for the current year,
but give you an indication that we're going to come to you a year before the current targets expire.
But our ambition is to keep growing the returns of the business and really important for me, not
just the returns, but the consistency and the stability of those returns.
So more in February, I'm afraid. Thank you. Next question please.
Amit Goel, Mediobanca
Two questions from me. One again, just on Best Egg, but just more in terms of USCB capital
allocation and growth plan. So, I guess this is presented very much as like a replacement for the
American Airlines portfolio in combination with General Motors. You've got the same kind of
receivables target and talking about the pro�tability. I'm just curious, if you'd retained the
American Airlines portfolio for example, would you still have done this transaction? How are you
thinking about allocation to the business going forwards, where pro�tability has been strong this
quarter.
The second question is actually just a bit more speci�c, but just on the deposit business within
BUK. Just curious what your thoughts are going into next year, because I think one of your peers
was talking about slightly slower growth. So just curious, what you are expecting and whether
that has any feed through to the hedge balance? Thank you.
Anna Cross
Let's just step back a little bit and think about what Best Egg does for USCB. It creates scale and
capability, and they are the things that we've talked about sort of repeatedly when we talked
about potential acquisitions. So, the loss of American Airlines clearly gave us a question on scale,
but the question of capability is somewhat beyond American Airlines. Clearly it's capital light
revenue, but I think, you know, this is digital �rst, [has] superior risk capability in an area adjacent
to what we already do. In fact, we are in this business in a small way. So, it's �rst and foremost a
capability purchase, and we've been talking to the business for nine months. That's really what
attracted us. Actually, the sort of to-ing and fro-ing in terms of scale, is somewhat an output.

-- 4 of 22 --

Investor Relations
5
However, as you point out, we're essentially taking a relatively low risk adjusted margin, capital
heavy source of revenue and replacing it with a capital light, high RoTE source of revenue. Growth
from here, we clearly see growth in this particular business because there are potential revenue
synergies there. I think that's not only from the Best Egg customers coming to us directly and us
being able to sell cards and deposits to them. It's clearly in the opposite direction, being able to
take that product into our full partner suite. We do it with about 10 partners at the moment to
give you an idea, but it is small. And then there are clearly revenue synergies in respect to funding
and also in securing our �ow of ABS business, if you like, into the Investment Bank. So, all of these
things are in our mind.
That said, the core business and our focus on improving the pro�tability of the core business in
USCB remains. So this is in no way a substitute for all of the stuf that we have been doing for a
number of quarters now, in which you're seeing in the Q3 results and we would expect to replicate.
But if the essence of your question is, should we expect to see a series of these in the US? The
answer to that is no. Because essentially this is about, as I said, �rmly a capability purchase. And
having got that capability, growth from here should be in scaling that business in a capital light
way and in continuing to grow our US cards business very much in the way that you've seen us do
it before, both organically and inorganically at the same kind of cadence.
Deposit businesses, particularly in BUK, I’d distinguish between deposit competition and trends,
and the hedge. So, what we've seen in the hedge is clearly deposit stability, particularly in the
hedgeable balances. So, the non-interest sensitive balances that we have, and that's allowed us
to give you some guidance that we expect to roll a 100% of the hedge from here. That's what
we've done for the last few quarters.
Contrast that with what we see as competition in the deposit market, which is really a churn in
the �xed term deposit book, whether they be ISA or not, and that's really what we saw in Q2. We
saw again in Q3, there were some very, very large maturities in the market in Q3 and therefore we
saw some intense pricing. Actually we expect that to continue and that's included in the margin
expectations that we've given you. Why do we expect it to continue? Well, in part, we can all
speculate as to why there's some extra competition in this market. It may be because of concerns
around ISAs, there's certainly TFSME (Term Funding Scheme with additional incentives for SMEs)
funding coming up for renewal and maybe broader re�ections on Quantitative Tightening. So, we
see that sort of �xed term competition continuing and that's really why we said to you in the
fourth quarter, expect that product margin element in the NII �ight path that we gave you,
remember it was very positive in Q3, we expect that to be broadly neutral in Q4. And that's
because of what we observe in deposits and also the comments that are made on the earnings

-- 5 of 22 --

Investor Relations
6
call in respect to mortgages. Clearly going in the opposite direction to those headwinds, we've
got the formation of IELs (Interest Earning Lending balances), we've also got the impact of
Kensington. So, for us it's broadly neutral, but we do see those margin impacts in the wider market.
Elise Yu-Ge, KBW
Thank you for taking my questions. I've got a slightly out the picture question if that's okay.
Stablecoins, just being something we've been talking about recently. I think Barclays has
previously spoken about its use case in the wholesale market and I think one of your peers, Lloyds,
has commented on the deposit usage in retail business. But the disclosure has been quite limited,
I guess the topic's quite new. Just interested to hear your views on [what the direction of travel
is], in terms of maybe costs or timeline or any regulatory challenges? Ultimately do you think it's
going to make a material diference for Barclays and your clients?
Anna Cross
Dan's been very involved in this.
Dan Fairclough, Group Treasurer
I think it's obviously a very interesting topic for us to watch. I mean, at the moment, I think the
stablecoin use case has primarily been crypto, of-ramp, on-ramp and some remittance activity.
I think sort of take up more broadly across international payments with corporates has still been
relatively limited, but I think that's where we see that it could have potential for further application.
I think the use case in retail is much less clear. It's obviously something that we will we'll watch
closely, but for a couple of reasons.
Firstly, I think the de�nition of stablecoin as money is still somewhat lacking, in con�dence and
security. Secondly, the use case in terms of the fact that retail domestic payments are already
pretty straightforward to do. So I think the use case for retail is much less clear. So we'll watch this
space really closely. As you know, there's been a press release on it, we're engaging with the other
UK banks on testing some of these technologies. And we'll be testing use cases there, both in the
wholesale space and also in the retail space. But the retail space, less stablecoin and more about
adding features to the existing form of money. So we'll be testing those, so a lot to watch, I think.

-- 6 of 22 --

Investor Relations
7
Sanjena Dadawala, UBS
The �rst on the Private Bank, on NII, which was down in the quarter, with increase in deposit
balances. So just thinking about going forward, if this is a start of a trend or if there are some one
ofs or things going on in the quarter in particular. The second on UKCB, the [income] expansion
again on the trend, is that something which continues into the future or is there a deposit mix
change driving that, which may slow down at some point?
Anna Cross
On the Private Bank, what we continue to see is our clients are very heavily engaged with us and
optimising their positions, whether that be across deposits or indeed investments. As
sophisticated investors, that's what we would expect them to do. And in that business, clearly we
are keeping that within the ecosystem, both in deposits and investments. So, broadly happy with
it, but it has somewhat eroded the NII in the quarter. We'd expect a broadly similar level of income
I think as we head into Q4, but just a re�ection, I guess, of the nature of the clients. Just to remind
you, I mean, that is a very, very high RoTE business and it remains above the target of greater than
25% that we've given you for 2026.
So if I go into the UK Corporate Bank, we've seen really good income growth there, there's nothing
in particular as a single matter I would call out. Just deposit growth and lending growth
fundamentally coming through into that top line into the NII.
Alvaro Serrano, Morgan Stanley
On the US Consumer Bank, obviously very good performance in Q3 means we look at Best Egg
with better eyes. I just wanted to understand better that improvement in performance, you called
out improving in loan pricing and also in fees. The revenue share agreements, some of them were
renegotiated. Can you maybe give us examples of how much the loan yields or loan spreads might
have gone up or how you compare to competition? Something that would give us a better sense
of how sustainable that is? I don't know if higher pricing might afect volume? Any examples of
those two things that can help us get our head around that?
And the second question is on the Investment Bank, you touched on it already, the RWA
e�ciencies. There's more to go, but if we think about the next plan or going forward, is the
philosophy still to keep RWAs �at in the business? And if that's the case, I don't know if you can

-- 7 of 22 --

Investor Relations
8
help us quantify those e�ciencies in particular in [Global Markets], because I realise M&A and ECM
don't really carry that much capital. Just to get a feeling of how much more room there is.
Anna Cross
So on USCB, I mean the improvement that you are seeing coming through does come in large part
from pricing. So, to give you an idea, the year-on-year improvements in NIM, about half of that
comes from the repricing that we did last year, and that repricing was completed by the end of
2024. But the way this works through into the NIM is that consumers have to repay and then draw
down on the new terms and conditions for that to really feed through into the NIM. There has been
wider repricing across the market. That came initially from the expectations of late fee reductions
last year and has not yet reversed. The impact for us in terms of late fees was relatively small, as
you can imagine, relative to some of our competitors. And therefore, we don't believe that it's
creating any kind of NIM competitive pressure.
For some of our competition late fees would be more signi�cant and therefore that might be more
of a question. But on another level, one of the things that we established as we prepared for our
strategy pre-February 2024, was we were not optimised for pricing, even on a like-for-like basis,
even pre the loss of late fees. So, much of this has been a bit of an industry catch up and therefore
has not really had a signi�cant impact, in terms of competitive positioning. So, we remain
comfortable where we are positioned and we do see it as sustainable in terms of the pricing.
I mean the other things that are directly impacting the NIM are the growth in retail deposits.
Remember there's a 50 to 60 basis points diferential there [versus wholesale lending] and also
the general expansion towards retail balances. Now, clearly in the quarter, there's only been one
month of General Motors. So revenue sharing arrangements, I'm not going to call any of them out.
We never do as a partner matter and they do actually impact both the NIM line and the non-NII
line. So that's why you're seeing some improvements there also, as well as there being just
generally increased volumes. So, underlying your question, is this sustainable? The answer is yes,
we do believe it is, which is why we said we expected NIM to be broadly stable from here. Just
remember it is quite a seasonal business, so you get some lumps and bumps particularly in Non-
NII. So we're happy with that general direction.
If I go onto the Investment Bank, what you've seen for the last six quarters is that the revenue
over RWAs continues to improve. So, if you look year-over-year across those six quarters, you can
see a step change each time and clearly what we were looking for at the beginning of the plan was
the area where revenue over RWAs had declined markedly over time, [which] was really in the

-- 8 of 22 --

Investor Relations
9
Banking business. And that's where we see a lot of the improvements starting to come through
in very, very good capital discipline in driving that Treasury Coverage model. So, you can see that
in the International Corporate Bank balances that are growing, and the income there, but also
really being focused in M&A and ECM and as I called out before, we do feel there's more to go in
those businesses.
So in terms of the Banking business, you would expect there to be further road to travel in terms
of this revenue over RWAs, because of the International Corporate Bank business continuing to
perform. Just because we still have ambitions within ECM and M&A, that they remain a focus for
us, but also just this kind of real discipline about the maturation of capital and really whether we
continue to extend it to that client or not, or choose to put it elsewhere. So much more to go, I
think tangibly within Banking.
But in the Markets business, clearly that was coming from a slightly diferent place. It wasn't a
situation where we deployed more capital into that business and that it had largely maintained its
revenue over RWAs. What you're seeing now is it continuing to improve because it is taking share,
and in many instances we'd already given capital to those focus businesses and they're sort of
growing into the capital and maturing into that capital. And then the other thing is obviously
Financing, a very capital light business, continues to grow, particularly on the Prime side where
the balances were 30% up year on year. So, I can't give you a speci�c target and indeed that's not
how we're thinking about this business in particular, because we do think of it in terms of RoTE.
So, it's a number of things to get there, but think of us as still feeling like there's room to go in
terms of that revenue over RWAs.
Nicolas Payen, Kepler Cheuvreux
A couple of questions please. The �rst one, back to Best Egg. You mentioned that the returns for
Best Egg are comparable to your three highest returning UK businesses. So essentially, we can
assume at least 20%. I just wanted to put that into the context of your mid-teens RoTE targets
post 2026. Is 20% something which is achievable over the long term?
Second one would be on the group income target of £30 billion for 2026. Consensus is actually
above that level, at £30.4 billion. So, I just want you to know if you're comfortable with that level
and should we think about £30 billion as a �oor? Thank you.

-- 9 of 22 --

Investor Relations
10
Anna Cross
On Best Egg, I mean, you're right. If you sort of back solve, actually with a total investment, you're
going to get to around the kind of level that you've talked about in time. Actually on a RoTE basis,
it'll be much, much higher. We've given you the price, you've got a P/E ratio, so you can determine
what the earnings are and the tangible equity is around $275 million. So, the RoTE is actually
incredibly high in this business. When we say it's sort of in alignment with the UK [businesses], I'm
being quite penal in that calculation because I'm including the goodwill essentially.
As for the entirety of the USCB targets, I would remain in my mid-teen zone. The bulk of the
business is the cards business. This business, whilst adding capability and adding scale, it is
relatively small, certainly at this point in time. Clearly something that we think we can scale, but
the most important part of the USCB story remains the improvement in the RoTE of the core
business. And that's clearly what we've focused on. That's what you saw in Q3.
As relates to, I think you're talking about the income expectations for 2026. Look back in 2024,
when we talked to you, we said we expected income of around £30 billion and costs of around £17
billion. We said that if income was higher or lower, then cost would be higher or lower. You know,
for us, RoTE is the north star, and that's really what we've been focused on, which is why we are
not really giving you an absolute income target. That was an indication.
That said, you can see from the momentum that we've had, that the top line is higher than we
expected it to be. That's why we've upgraded our Group NII [excluding IB and Head O�ce]
expectation this year. Clearly, historically that's come over time from the rate environment that
we're in, but it's also coming from the increasing con�dence that we have from USCB and the
progress that it's making. So, I’d call out that NII trajectory as being particularly strong. We clearly
where we want to be in terms of UK lending momentum, and that's not going to stop at the end
of 2025 or indeed 2026. Then the other thing I would just call out is the two businesses where,
they've been somewhat of a drag on Group RoTE or earnings, are clearly now making progress.
So, I would say the momentum is with us, but obviously we'll guide you more �rmly in February.
Benjamin Toms, RBC
Firstly on Corporate lending, you mentioned it earlier about how good the performance has been,
and that wasn't just a Barclays story, that's across the UK Corporate Bank. So I was hoping you

-- 10 of 22 --

Investor Relations
11
could unpick some of the drivers of why you think growth has been so good there and to what
extent will the underlying continue into the end of this year and into next year.
Secondly, on building out the Investment Bank, I think you're looking to go back into Saudi Arabia.
If you could just kind of give some colour about what the ambitions are there. You spoke earlier
about how your performance was not so good versus peers because of lacking Equity Derivatives
in Asia. To what extent you have appetite of kind of rectifying that, either inorganically or
organically?
Anna Cross
On UK Corporate Bank, we are really pleased with the performance and clearly it's taken a while
for us to get to this momentum. I think there's a couple of things really underpinning it. One is
actually saying that you are open for business with your clients. I think that's really important,
because about half of the new lending that we've done has come from existing clients. I think that
gives the con�dence to those clients, it gives a con�dence to the regional teams that are dealing
with them directly. So, that's a really important statement.
The other piece, however, that's made a real diference, and it's a bit like what we've done in
mortgages or what we've done in cards, is there's an adjacent capability build that we've done
here. That's not just digital, but actually the speed to the lending decision is markedly improved.
So that's a better client experience. But again, I said half of the lending was coming from existing
clients. Well, the other half has clearly come from new clients. So, we have been acquiring clients
550 last year, more than 400 this year so far. 	But there's no particular concentration
geographically or by sector or anything. It is just capability build and focus that's bringing that
through. So very much the same risk. So, no change in our risk appetite again, like our strategy in
cards. I think the other thing that I would call out, and it's in the back of the [Investor Presentation
on slide 35] where we talk about the survey, about 43% of our clients say that they expect to make
investment decisions beyond the budget. So, there is a slight hesitancy in the market, probably
more in the mid-corporate area, not really holding us back, but clearly there are some thoughts
from some of those clients there.
In terms of Saudi Arabia, I'm not going to make speci�c comments on Saudi Arabia here. I don't
think you should see it as the harbinger of a substantial move eastward. So, I don't see us
reestablishing the position that we exited in Asian Equities in the 2010s. Those comments were
more of a re�ection of the fact, in some quarters, our business focus will help us excel and in some

-- 11 of 22 --

Investor Relations
12
quarters it will be a relative headwind for us. So, it was a statement rather than a statement of
ambition. But in terms of Saudi Arabia, nothing I would particularly add beyond what we've put in
the press at this point in time.
Kian Abouhossein, JPMorgan
The �rst question, just coming back to Equity Derivatives in Asia, you mentioned, you don't have
a retail business, but if I look at the largest players, they don't have a retail business either. These
are the Americans who control the market. So, I'm just trying to understand, your position
compared to your peer group really, which is mainly doing Chinese corporate ofshore/onshore
derivative business. That's where the money is rather than retail. Just want to understand what
business do you think you're not doing, which leads to a weaker position.
The second question I have is on Financing, you've done a great job of growing Financing. Is there
any leverage exposure limitations that you think of? In that context, is there any more detail you
can give us on Financing in terms of segmentation? What is actually in the Financing book?
Anna Cross
Okay, let me start, and I might ask Dan to add to the leverage part of the question. On Equity
Derivatives, we feel like there were comments out there in the market around Retail and Wealth,
that was our broader understanding. Some of them do have Retail and Wealth businesses, so
that's clearly helped their businesses. For us, I'll go back to what I said before, don't expect us to
have a signi�cant Asian Equities business. Equity Derivatives is one of the focus areas that we
called out right at the beginning of the plan. An area where we felt we really wanted to build
capability. It’s one where we've monetised the market well, when there's been volatility, less so
when there hasn't. And that's clearly something we are re�ective of Kian, and an area that we,
clearly given the Q3 results, need to keep working on. So that's how I'd characterise it.
On Financing, here we're talking about our Prime business and our Fixed Income Financing
business, predominantly with hedge funds, that's what we're discussing here. The largest part of
the growth is really coming through Prime, where our balances have been up signi�cantly year-
on-year. There is an Asian element to that growth. Clearly that's a wider margin than we would
see on the other side of the business in Fixed Income Financing. And it's an area that we want to
continue to grow. As you call out, it's RWA light, but it is leverage heavy. We are very thoughtful
really about the interplay between AT1 and the returns on that business. But Dan, you might want
to add.

-- 12 of 22 --

Investor Relations
13
Dan Fairclough
Yeah, just to add a little bit more �avour in the business. Obviously, leverage is the lifeblood for
that business, but we've got the same focus on e�ciency in that business as we do elsewhere on
RWAs, so exactly the same principles apply. We're very focused on the return on leverage balance
sheet versus the cost, particularly the cost of AT1. In terms of a bit of the �avour of the business,
it's also quite consistent. It's very focused on the top clients. That's really where we spend most
of our energies and time. It's just extremely high-quality liquid book serving that client base.
Sheel Shah, JPMorgan
Two questions please. First, coming back to Best Egg, because it isn't a bank and it's clearly being
acquired by a bank. Would the rules have to change with regards to holding an equity slice, or a
tranche of the securitisations? Could you speak to maybe how that works, for Barclays?
Then secondly, looking at the SRT book, I know you haven’t given disclosure for the third quarter,
but for the second quarter, it's declined about £7 billion. So, I'm just wondering, is that a timing
issue or how should we think about that, and how does that tally with the capital e�ciency in the
Investment Bank?
Anna Cross
In terms of Best Egg, you're right, it's not a bank, it does become part of one as this transaction
completes. There are implications of that in terms of its funding. Obviously creates some
e�ciencies. In terms of the regulatory requirements around the slice that it holds, I don't believe
that they are signi�cantly diferent, but we can revert. But I don't believe so, Dan may want to add
to that.
So, from our perspective, given its business model and given the way we are already embedded
in that business model in the Investment Bank, actually we see e�ciencies here, because we have
the pre-securitisation funding opportunity. We clearly have reduced securitisation costs because
there are things that we will be doing in house. We have an ability also to have a �ow of consumer
credit into that ABS business. So, from our perspective, it's a net bene�t in that particular part.
Dan, SRT?

-- 13 of 22 --

Investor Relations
14
Dan Fairclough
There’s a very consistent level of activity in SRT, so there's nothing I would call out. Maybe we can
follow up with you afterwards on whether there's FX or amortisation. There are numbers, but the
footprint has been very, very consistent.
Anna Cross
Again, that's sort of consistent with what we've said before. We do see that Colonnade program
in particular as being a mature program and we manage it carefully in terms of its reinvestment
cadence. So, I think it's probably in the detail rather than anything deliberate.
Canberk Benning, Citi
On Tricolor, could you elaborate on the nature of Barclays' exposure to Tricolor? Was it primarily
warehouse lending, securitisation, or another form of structured �nance? Just a comment on
whether you think this is more of an idiosyncratic trend, or are you worried about broader trends
in the market?
Then on the Investment Bank, you noted in the call last week that there will be difering trends in
each quarter. So, this quarter was APAC performing particularly well. I was just wondering if you
could elaborate or clarify the trends that you see going forward, and which parts of the
Investment Bank have the most momentum?
Anna Cross
In Tricolor, clearly, we were lenders into that warehouse. We said on the call that it was a client for
many years for the bank. It had been a client for 9 or 10 years. So we've been very re�ective of
really the indicators that had become apparent in that business that might have led us to discover
that particular situation. Now clearly from our perspective, the �rst line of defence is the clients
that you choose at the outset. Tricolor had clearly been a client for a long time and a good one for
a long time. There are other clients that we have not onboarded. Then once those clients are
onboarded, what monitoring do you do? And we've been re�ective of a couple of things.
Firstly, what are the controls and, in particular the separation of controls within the vehicle itself.
So, who's managing the collateral versus managing the business, and the independence of that is
something that we've considered. Also, quite frankly, who are the advisors, the accountants, et

-- 14 of 22 --

Investor Relations
15
cetera for that business. So, we've looked across the rest of the businesses with those thoughts
in mind, and there's nothing that we've seen that's concerned us. Clearly, we're watchful as we
always are.
In terms of the broader trends on the Investment Bank, clearly what we've seen is a reawakening
of the Banking market, particularly in the US. We've bene�ted from, as I mentioned in my prepared
remarks, the resurgence within DCM, so that's a business that we are well geared to service. We
feel like we've made good progress in terms of sponsors generally, but particularly in M&A.
The areas where we've been mindful of our relative performance, as I said, were corporates in
M&A and ECM. Now in the quarter, we didn't participate in the largest deals. Again, that's
something we are re�ective of, but as I look forward into Q4 and beyond, really the ECM pipeline
looks better, but we are very mindful of government shutdown in the US and the kind of impact
that might have on the timing of transactions, so that's the only thing I would say. For the Markets
business, it's very di�cult to call a trend a quarter ahead and I won't attempt to do so.
Christopher Cant, Autonomous
On Best Egg, in terms of the �nancials here, you've given us the high single digit P/E of something
like a £90 million bottom line. I think you've indicated that the ROIC (Return on Invested Capital) is
going to be commensurate with the UK businesses, if I've understood you correctly. So, £90m
[bottom line] versus your £800m investment seems to imply quite a meaningful amount of cost
synergy that you expect to deliver over time. I'm just mindful of that implying potentially a step
up in costs in USCB as we look into 2026. I'm just curious if you could give us an indication of the
cost base that's attached to this. Appreciate you've sort of indicated the revenues are
commensurate with the American Airlines book, but just in terms of the cost, that would be
helpful, I think for our modelling.
Then in terms of the longer-term capital allocation question, it came up on the call last week.
There's obviously market sensitivity around your 50% Investment Bank allocation target. I guess
the $40 billion end net receivables target [in USCB], you weren't necessarily expecting quite so
much of it to be servicing relationships when you set out the strategic plan. So, the $16 billion
card IRB impact, it would just be scaling that down by $4-5 billion for the fact that, out of the $40
billion of targeted balances, over a quarter is now of-balance sheet and therefore presumably be
not impacted at all by IRB.

-- 15 of 22 --

Investor Relations
16
Anna Cross
You‘re sort of broadly at the right sort of earnings level. I think as an ROI matter, what we're saying
is in time you're right, we do expect to grow the earnings of this business, and I would say probably
in the following order. Starting with funding synergies. Again, remember that's what we did in
Tesco, they're the ones that normally come through �rst and I called those out before. Remember,
this isn't a bank at the moment. So, there are clear funding synergies in terms of the pre-
securitisation position, the cost of securitisation itself. Then you come to cost synergies, for a
while we would expect to run this as a business in parallel and then incur the integration over time.
So I wouldn't call out any particular integration chunks next year, but clearly, we'll update you on
that. But funding is a key point.
And I also think those revenue synergies are going to come from a number of diferent places. So,
as I said before, it's cross selling cards and deposits to customers who come to us via Best Egg.
It's going in the opposite direction and extending the Best Egg capability across all of our partners
into the cards business. It's also actually about our ability to create a forward �ow of consumer
business into our Investment Bank, so that's also important here. I think funding, revenue and
costs will come in time, but we do have con�dence that we can get this to high teens RoTE.
On the Investment Bank, clearly when we set that 50% [target] out, there was an expectation of
timing of regulatory change, and that's clearly changed over time. That $16 billion was therefore
related to a level of balances that was not $40 billion. So I think that's the �rst thing to remember,
because we expected to go through AIRB actually in 2025, it seems like quite a long time ago, but
I'm sure our original expectation was 2025, by which time the balances would not have been $40
billion. So, I wouldn't necessarily do the kind of scaling that that you're talking about here.
That said, you are right, we've replaced capital heavy balances with capital light balances.
Although we'll retain a small portion of the loans, the AIRB treatment of loans is relatively much
lower than it is for cards. So you're not really going to see a material step change there, both
because of the nature of the change and also because of the quantum.
But the 50%, or the spirit behind the 50%, remains intact, which was about holding the
Investment Bank [RWAs] �at. You should expect us to continue to do that and expect us to
continue to grow the UK in particular. And it was really the UK growth that was driving that change.
The regulatory change is timing and at the point where we have a better estimate of that $16
billion, we will of course come to you with it. But unfortunately, the quantum and the timing has
some regulatory uncertainty around that.

-- 16 of 22 --

Investor Relations
17
Chris Hallam, Goldman Sachs
Just two questions, both on the US. First of all, you mentioned the shutdown, the impact that
could have on Q4 revenues. Should we think about that just as, if the shutdowns still there on
November 6th, accounts have gone stale, all the ECM has pushed into Q1. Is that the right way to
think about it? Maybe also, does that difer for M&A versus ECM?
And then on the second side, I think the Federal Reserve has provided its proposals for the
simpli�cation or the increased transparency on CCAR. So just any initial thoughts you have with
regards to either for yourselves or for your peers in the US.
Anna Cross
We would see a shutdown as a relative timing point, irrespective of the line in Banking that we're
talking about, whether it's ECM or M&A. To the extent that they're strategically important to
those clients, we'd still expect them to complete, they just might get pushed. So that's how we'd
see it certainly at this point in time, given this length of delay.
In terms of CCAR, and I would say more broadly around the US regulatory emergence, what
appears to be a general theme as transparency and coherence. By that I mean the way in which
the various aspects of the regulations �t together, whether that be CCAR, whether that be GSIB,
whether that be leverage, whether it be Basel. And actually the way the Fed is sort of stepping
back and re�ecting on those things as a coherent whole, we would welcome, and we remain
hopeful that the FPC will take a similar approach.
James Invine, Rothschild & Co Redburn
I wanted to ask about the Financing Business, please. I mean, that's been working well for you. As
Dan said earlier, you've been focused on the largest of the hedge funds. But, from what we can
see, and I think disclosure across the industry isn't very good here, but from what we can see,
your penetration into those very largest hedge funds is now approaching the kind of top three
Financing �rms to the big US banks. But where you have less penetration is in kind of the next rung
down. Is there still a lot more scope, you think to increase penetration further and really kind of
catch up or maybe even overtake the biggest players in the industry among that top group of
hedge funds? Or are you going to have to start focusing more on the next rungs down?

-- 17 of 22 --

Investor Relations
18
Anna Cross
Our Financing business is working well and remember this comes in two parts. So, our Fixed
Income Financing business, very much embedded in the heritage of Barclays and Lehman before
it. It is typically number one or two in the market. So very, very well-established business. What
we've been doing is growing Prime alongside that. We've gone from typically number seven or
eight to joint number �ve. So, we've clearly made some progress there. As you note, our targeting
has been with the larger of the hedge funds, that's deliberate, and it re�ects both our business
model and our view of risk. So by business model, what I mean is we run our Financing business
as an integrated business.
So Fixed Income Financing and Prime are run under a single leadership. So when we approach a
client, that's how we approach them, not as two individual businesses. We also run our
technology that way. So, as we're looking at those clients, we look across their business in its
totality, and we believe that gives us a better perspective of their risk. That lends itself to the
largest global multi-strategy type funds, so that's really why you see that approach. But also, in
terms of our own risk positioning, we do believe that, again, the �rst step in risk management is
through the careful selection of clients, and therefore we choose to work with the larger, more
capitalised, more liquid clients in the industry. That's really where we prefer to operate. That may
mean that we give up a little margin along the way, but that certainly is a risk matter where we
would want to operate. So, it's a deliberate strategy. So, from our perspective, we would want to
grow as they do. Clearly, we do feel there's more for us to do there.
Thank you so much. Really appreciate you coming in again on a very busy day in the market. So,
appreciate your time and questions, particularly on Best Egg. We will see you on the 10th of
February, if not before. Thank you very much.

-- 18 of 22 --

Investor Relations
19
Important Notice
The terms Barclays or Group refer to Barclays PLC together with its subsidiaries. The information,
statements and opinions contained in this presentation do not constitute a public ofer under any
applicable legislation, an ofer to sell or solicitation of any ofer to buy any securities or �nancial
instruments, or any advice or recommendation with respect to such securities or other �nancial
instruments.
Information relating to:
• 	regulatory capital, leverage, liquidity, resolution and related regimes is based on Barclays'
interpretation of applicable rules and regulations as in force and implemented in the UK
as at the reporting date, including, but not limited to: CRR; the PRA Rulebook; and any
applicable delegated acts, implementing acts or technical standards; in each case as
amended and, where applicable, as such rules and regulations form part of domestic law
by virtue of the European Union (Withdrawal) Act 2018. All such regulatory requirements
are subject to change and disclosures made by the Group will be subject to any resulting
changes. The Pillar 2A requirement is also subject to at least annual review;
• 	MREL is based on Barclays' understanding of the Bank of England’s Statement of Policy on
"The Bank of England's approach to setting a minimum requirement for own funds and
eligible liabilities (MREL)" published in December 2021, and its MREL requirements
communicated to Barclays by the Bank of England. MREL requirements remain subject to
change, as determined by the Bank of England, taking into account a number of factors as
described in the policy, along with international developments;
• 	future regulatory capital, leverage, liquidity, funding and/or MREL, including forward-
looking illustrations, are provided for illustrative purposes only and are not forecasts of
Barclays’ results of operations or capital position or otherwise. Illustrations regarding the
capital �ight path, end-state capital evolution and expectations and MREL build are based
on certain assumptions applicable at the date of publication only which cannot be assured
and are subject to change.
Non-IFRS performance measures
Barclays’ management believes that the non-IFRS performance measures included in this
presentation provide valuable information to the readers of the �nancial statements as they
enable the reader to identify a more consistent basis for comparing the businesses’ performance
between �nancial periods and provide more detail concerning the elements of performance
which the managers of these businesses are most directly able to in�uence or are relevant for an

-- 19 of 22 --

Investor Relations
20
assessment of the Group. They also re�ect an important aspect of the way in which operating
targets are de�ned and performance is monitored by Barclays’ management. However, any non-
IFRS performance measures in this presentation are not a substitute for IFRS measures and
readers should consider the IFRS measures as well. Refer to the appendix of the Barclays PLC
Results Announcement for each of the periods ended 30 June 2019, 30 June 2021, 30 June 2023,
30 June 2024, 30 September 2024, 31 December 2024 and 31 March 2025 and the Group
Reporting Changes 2023 Results Resegmentation Document, respectively, which are available at
Barclays.com, for further information and calculations of non-IFRS performance measures
included throughout this presentation, and the most directly comparable IFRS measures.
Forward-looking statements
This document contains certain forward-looking statements within the meaning of Section 21E
of the US Securities Exchange Act of 1934, as amended, and Section 27A of the US Securities Act
of 1933, as amended, with respect to the Group. Barclays cautions readers that no forward-
looking statement is a guarantee of future performance and that actual results or other �nancial
condition or performance measures could difer materially from those contained in the forward-
looking statements. Forward-looking statements can be identi�ed by the fact that they do not
relate only to historical or current facts. Forward-looking statements sometimes use words such
as ‘may’, ‘will’, ‘seek’, ‘continue’, ‘aim’, ‘anticipate’, ‘target’, ‘projected’, ‘expect’, ‘estimate’, ‘intend’,
‘plan’, ‘goal’, ‘believe’, ‘achieve’ or other words of similar meaning. Forward-looking statements
can be made in writing but also may be made verbally by directors, o�cers and employees of the
Group (including during management presentations) in connection with this document.
Examples of forward-looking statements include, among others, statements or guidance
regarding or relating to the Group’s future �nancial position, business strategy, income levels,
costs, assets and liabilities, impairment charges, provisions, capital leverage and other regulatory
ratios, capital distributions (including policy on dividends and share buybacks), return on tangible
equity, projected levels of growth in banking and �nancial markets, industry trends, any
commitments 	and 	targets 	(including 	environmental, 	social 	and 	governance 	(“ESG”)
commitments and targets), plans and objectives for future operations, International Financial
Reporting Standards (“IFRS”) and other statements that are not historical or current facts. By
their nature, forward-looking statements involve risk and uncertainty because they relate to
future events and circumstances. Forward-looking statements speak only as at the date on which
they are made. Forward-looking statements may be afected by a number of factors, including,
without limitation: changes in legislation, regulations, governmental and regulatory policies,
expectations and actions, voluntary codes of practices and the interpretation thereof, changes

-- 20 of 22 --

Investor Relations
21
in IFRS and other accounting standards, including practices with regard to the interpretation and
application thereof and emerging and developing sustainability reporting standards (including
emissions accounting methodologies); changes in tax laws and practice; the outcome of current
and future legal proceedings and regulatory investigations; the Group’s ability along with
governments and other stakeholders to measure, manage and mitigate the impacts of climate
change efectively or navigate inconsistencies and con�icts in the manner in which climate policy
is implemented in the regions where the Group operates, including as a result of the adoption of
anti-ESG rules and regulations, or other forms of governmental and regulatory action against
ESG policies; environmental, social and geopolitical risks and incidents and similar events beyond
the Group’s control; �nancial crime; the impact of competition in the banking and �nancial
services industry; capital, liquidity, leverage and other regulatory rules and requirements
applicable to past, current and future periods; UK, US, Eurozone and global macroeconomic and
business conditions, including in�ation; volatility in credit and capital markets; market related
risks such as changes in interest rates and foreign exchange rates; reforms to benchmark interest
rates and indices; higher or lower asset valuations; changes in credit ratings of any entity within
the Group or any securities issued by it; changes in counterparty risk; changes in consumer
behaviour; changes in trade policy, including the imposition of tarifs or other protectionist
measures; the direct and indirect consequences of the con�icts in Ukraine and the Middle East on
European and global macroeconomic conditions, political stability and �nancial markets; changes
in US legislation and policy following the US elections in 2024; developments in the UK’s
relationship with the European Union; the risk of cyberattacks, information or security breaches,
technology failures or operational disruptions and any subsequent impact on the Group’s
reputation, business or operations; the Group’s ability to access funding; and the success of
acquisitions (including the acquisition of Tesco Bank completed in November 2024), disposals,
joint ventures and other strategic transactions. A number of these factors are beyond the Group’s
control. As a result, the Group’s actual �nancial position, results, �nancial and non-�nancial
metrics or performance measures or its ability to meet commitments and targets may difer
materially from the statements or guidance set forth in the Group’s forward-looking statements.
In setting its targets and outlook for the period 2024-2026, Barclays has made certain
assumptions about the macroeconomic environment, including, without limitation, in�ation,
interest and unemployment rates, the diferent markets and competitive conditions in which
Barclays operates, and its ability to grow certain businesses and achieve costs savings and other
structural actions. Additional risks and factors which may impact the Group’s future �nancial
condition and performance are identi�ed in Barclays PLC’s �lings with the US Securities and
Exchange Commission (“SEC”) (including, without limitation, Barclays PLC’s Annual Report on

-- 21 of 22 --

Investor Relations
22
Form 20-F for the �nancial year ended 31 December 2024), which are available on the SEC’s
website at www.sec.gov.
Subject to Barclays PLC's obligations under the applicable laws and regulations of any relevant
jurisdiction (including, without limitation, the UK and the US) in relation to disclosure and ongoing
information, we undertake no obligation to update publicly or revise any forward-looking
statements, whether as a result of new information, future events or otherwise

-- 22 of 22 --